# Atezolizumab-Induced Generalized Cutaneous Lichen Planus in a Patient With Metastatic Small Cell Lung Cancer Successfully Treated With Isotretinoin: A Case Report

**Authors:** Cătălina-Ioana Naum, Beatrice Bălăceanu-Gurău, Alexandra Timofte, Irina Tudose, Mara M Mihai

PMC · DOI: 10.7759/cureus.77579 · Cureus · 2025-01-17

## TL;DR

A patient with lung cancer developed a rare skin condition from a cancer drug and was successfully treated with isotretinoin.

## Contribution

This case report highlights isotretinoin as a potential treatment for atezolizumab-induced lichen planus.

## Key findings

- Low-dose isotretinoin combined with topical corticosteroids effectively managed generalized cutaneous lichen planus.
- Isotretinoin may enhance the effects of topical corticosteroids through synergistic interaction.
- Isotretinoin's anti-inflammatory and immune-modulating properties may benefit lichen planus treatment.

## Abstract

Immune checkpoint inhibitors, now widely used in treating various malignancies, increase the risk of autoimmune reactions and immune-related adverse events (irAEs), with skin toxicities being the most frequent. These agents enhance the immune response against tumors by blocking the suppression of cytotoxic T lymphocytes.

Here, we report a rare case of generalized cutaneous lichen planus induced by atezolizumab, an immune checkpoint inhibitor administered for small cell lung cancer. After consulting with the oncologist, we opted to initiate isotretinoin as the first-line treatment. Considering the patient's oncologic status and multiple comorbidities, we aimed to avoid systemic corticosteroids due to their potential side effects.

This case was effectively managed with low-dose oral isotretinoin alongside high-potency topical corticosteroids. It emphasizes the need to consider retinoids as a potential treatment option for various dermatological conditions beyond acne. Isotretinoin may be beneficial in treating lichen planus by influencing cellular proliferation and promoting epithelial differentiation, though its exact mechanism remains uncertain. Additionally, it has notable anti-inflammatory effects and modulates immune responses. In such cases, isotretinoin may also enhance the therapeutic effects of topical corticosteroids through a synergistic interaction.

## Linked entities

- **Chemicals:** isotretinoin (PubChem CID 5282379)

## Full-text entities

- **Diseases:** immune-related adverse (MESH:D007154), malignancies (MESH:D009369), autoimmune reactions (MESH:D001327), inflammatory (MESH:D007249), skin toxicities (MESH:D012871), Cutaneous Lichen Planus (MESH:D008010), acne (MESH:D000152), Small Cell Lung Cancer (MESH:D055752), oncologic (MESH:D000072716), dermatological conditions (MESH:D000168)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11830495/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11830495/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC11830495/full.md

---
Source: https://tomesphere.com/paper/PMC11830495